- Home
- PHI vs ACLX Comparison
PHI vs ACLX Comparison
Compare PHI & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHI | ACLX |
|---|---|---|
| Founded | 1928 | 2015 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.2B |
| IPO Year | 1953 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PHI | ACLX |
|---|---|---|
| Price | $21.83 | $68.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $115.71 |
| AVG Volume (30 Days) | 67.2K | ★ 1.4M |
| Earning Date | 11-11-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.54% | N/A |
| EPS Growth | ★ 9.36 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $3,761,997,877.00 | $35,898,000.00 |
| Revenue This Year | $2.70 | N/A |
| Revenue Next Year | $2.64 | $302.49 |
| P/E Ratio | $9.38 | ★ N/A |
| Revenue Growth | ★ 1.69 | N/A |
| 52 Week Low | $18.61 | $47.86 |
| 52 Week High | $25.12 | $94.07 |
Technical Indicators
Market Signals| Indicator | PHI | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 35.94 |
| Support Level | $21.51 | $68.64 |
| Resistance Level | $22.20 | $73.98 |
| Average True Range (ATR) | 0.32 | 4.69 |
| MACD | -0.13 | -0.20 |
| Stochastic Oscillator | 29.63 | 18.18 |
Price Performance
Historical ComparisonAbout PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.